Trials / Completed
CompletedNCT00973115
Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia
Efficacy and Safety of Morning Versus Evening Intake of Simvast CR Tablet in Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 3 Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of morning versus evening intake of Simvastatin Controlled Release tablet 20mg for 8 weeks in patients with hyperlipidemia. This study will investigate equivalence of the low-density lipoprotein(LDL) cholesterol percent change.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Simvastatin CR |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-09-09
- Last updated
- 2016-10-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00973115. Inclusion in this directory is not an endorsement.